Iron chelation

DRUG2 trials

Sponsors

St. Jude Children's Research Hospital, University of Michigan Rogel Cancer Center

Conditions

Allogeneic Stem Cell TransplantAnemia, Sickle CellCerebrovascular AccidentHematologic DiseasesHemochromatosis

Phase 2

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

RecruitingNCT06784336

University of Michigan Rogel Cancer CenterAllogeneic Stem Cell Transplant

Start: 2025-10-15End: 2029-10-01Target: 50Updated: 2026-07-21

Phase 3

Stroke With Transfusions Changing to Hydroxyurea

TerminatedNCT00122980

St. Jude Children's Research HospitalAnemia, Sickle Cell, Cerebrovascular Accident, Hematologic Diseases +1

Start: 2006-10-31End: 2010-12-31Updated: 2013-01-18

Related Papers

Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia

JMIR Research Protocols2017-06-028 citations

Effects of Chronic Transfusion Therapy on MRI and MRA in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Imaging from the Twitch Trial

Blood2014-12-068 citations

Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial

Blood2014-06-1086 citations

Pain and other non‐neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: Results from the SWiTCH clinical trial

American Journal of Hematology2013-07-1648 citations

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.

2011-08-0853 citations

Secondary prevention of overt strokes in sickle cell disease: therapeutic strategies and efficacy.

2011-01-0111 citations